FDA expands indication for two transcatheter aortic valves
Editor's Note
The Food and Drug Administration (FDA) on August 18 approved an expanded indication for the Sapien XT and Sapien 3 transcatheter heart valves for patients with aortic stenosis.
The new indication is for patients who are at intermediate risk for death or complications associated with open-heart surgery.
Previously, these devices were only approved in patients at high or greater risk for death or complications during surgery.
The U.S. Food and Drug Administration today approved an expanded indication for the Sapien XT and Sapien 3 transcatheter heart valves for patients with aortic valve stenosis who are at intermediate risk for death or complications associated with open-heart surgery. These devices were previously approved only in patients at high or greater risk for death or complications during surgery.
Free Daily News
- HCA Healthcare reports solid first-quarter financials
- Per-person healthcare spending grows nearly 19% in 5 years
- OR Manager Conference: Lowest rates expire in one week
- Hospitals boost cybersecurity budgets, staff
- Kentucky passes first-ever state law decriminalizing medical mistakes
- Kaiser Permanente data breach affects 13.4 million
- Study explores link between diverticulitis and colorectal cancer
- State lawmakers target rising healthcare costs via legislation on hospital facility fees
- FDA medical device Class 1 recalls trend upward
- Data cast doubt on recommendation to delay weight-loss meds prior to surgery